Interpreting the Results of the ELEVATE-TN Trial for Treatment-Naive CLL
Nakhle Saba, MD, discusses the significance of the key findings of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab for patients with chronic lymphocytic leukemia.